SUBSCRIBE
SUBSCRIBE

Northstar Medical Radiosotopes

IN THE PRESS
Business
NorthStar Medical Radioisotopes and Curadh MTR Enter Strategic Collaboration Agreement for Development and Production of Actinium-225 (Ac-225)-based Therapeutic Radiopharmaceuticals for Treatment of Primary and Metastatic Solid Tumors
January 3, 2024
 · 
5 min read
BioMidwest
NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Truist Securities Biopharma Symposium
November 6, 2023
 · 
3 min read
Business
NorthStar Medical Radioisotopes and Curadh MTR Announce a Strategic Long Term Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)
August 29, 2023
 · 
6 min read
Drug Development
First Participant Treated Using NorthStar Medical Radioisotopes’ Electron Accelerator-produced Copper-67 (Cu-67) in Clarity Pharmaceuticals’ Phase I/IIa Theranostic Clinical Trial Investigating Cu-67 SARTATE for Treatment of Neuroblastoma
August 28, 2023
 · 
8 min read
Business
NorthStar Medical Radioisotopes Executes Supply Agreement with Bayer for Therapeutic Radioisotope Actinium-225 (Ac-225)
July 18, 2023
 · 
3 min read
BioMidwest
NorthStar Medical Radioisotopes Announces Supply Agreement with Nucleus RadioPharma for Alpha-emitting Therapeutic Radioisotope Actinium-225 (Ac-225)
June 27, 2023
 · 
5 min read
BioMidwest
NorthStar Medical Radioisotopes Now Routinely Manufacturing High Activity Copper-67 on its Electron Accelerators for Clarity Pharmaceuticals’ Therapy Clinical Programs
June 26, 2023
 · 
8 min read
BioMidwest
NorthStar Medical Radioisotopes Announces Participation in Upcoming 2023 Guggenheim Radiopharmaceuticals Day
May 9, 2023
 · 
2 min read
Business
NorthStar Medical Radioisotopes Announces Promotion of Jason Vinyard, MBA, MHA, to Vice President, Business Development, Therapeutic Technologies
April 12, 2023
 · 
4 min read
BioMidwest
NorthStar Medical Radioisotopes Announces Presentations at Upcoming Jefferies Radiopharma Innovation Summit
March 30, 2023
 · 
2 min read
Load More
JOBS